U.S. health insurer Anthem Inc. said it will exit Obamacare markets in Virginia and reduce its plan offerings in Washington and Scott counties and the city of Bristol in 2018.

U.S. health insurer Anthem Inc. said it will no longer offer Obamacare plans in Nevada’s state exchange and will stop offering the plans in nearly half of Georgia’s counties during 2018.

Aetna Inc. reported a higher-than-expected second-quarter 2017 profit as member health costs were lower than anticipated and it benefited from exiting most of its Obamacare individual insurance markets in 2017.

Anthem Inc. said it may exit more individual Obamacare markets as the future of the national healthcare law and the government subsidies that make insurance affordable for millions of Americans remain up in the air.

Health insurer Anthem Inc. filed a lawsuit against Insys Therapeutics Inc., alleging the drugmaker fraudulently obtained reimbursements for its opioid painkiller Subsys.

U.S. Attorney General Jeff Sessions will unveil a major crackdown on healthcare fraud involving opioid treatment programs, Bloomberg News reported, citing two people familiar with the matter.

Medtronic Plc said it signed an agreement with health insurer Aetna Inc. under which payment for its insulin pump systems will be tied to how well diabetes patients fare after switching from multiple daily insulin injections.

Centene Corp., one of the largest players in the Obamacare individual insurance market, said it would expand into three new states in 2018 despite uncertainty over the future of the legislation under President Donald Trump’s administration.

The U.S. Supreme Court cut the time it will take for copycat versions of biologic drugs to get to the market in a pivotal ruling about an expensive class of medicines.

New cancer drugs that target genetic mutations regardless of where the tumor is growing should expand the practice of testing patients for such glitches, oncology experts say.